Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OAKTREE: GS-5245 for Treatment of COVID-19 in Nonhospitalized Adults
jRCT2031230285Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Aug 2033
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing GS-5245 with Placebo (2 arms). Primary endpoint: Time to COVID-19 symptom alleviation by Day 29. Planned start Aug 2033; status: completed.
02
Drugs
obeldesivir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCT2031230285.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230285.